Cargando…
Cost-Effectiveness Analysis of Rivaroxaban Plus Aspirin Compared with Aspirin Alone in Patients with Coronary and Peripheral Artery Diseases in Italy
BACKGROUND: Rivaroxaban is a selective inhibitor of coagulation factor Xa and its combination with aspirin showed better outcomes in the prevention of recurrent cardiovascular disease than aspirin alone. OBJECTIVE: This analysis aimed to economically compare the cost effectiveness of rivaroxaban (2....
Autores principales: | Ferrara, Pietro, Cortesi, Paolo A., Di Laura, Danilo, Maggioni, Aldo P., Mantovani, Lorenzo G. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8149345/ https://www.ncbi.nlm.nih.gov/pubmed/33725323 http://dx.doi.org/10.1007/s40261-021-01023-8 |
Ejemplares similares
-
Commentary: Cost-Effectiveness Analysis of Rivaroxaban Plus Aspirin Compared With Aspirin Alone in Patients With Coronary and Peripheral Artery Diseases in Italy
por: Rawal, Shalin, et al.
Publicado: (2022) -
Rivaroxaban With or Without Aspirin in Patients With Heart Failure and Chronic Coronary or Peripheral Artery Disease: The COMPASS Trial
por: Branch, Kelley R., et al.
Publicado: (2019) -
Comparison of Aspirin and Rivaroxaban Plus Aspirin in the Management of Stable Coronary Artery Disease or Peripheral Artery Disease: A Systematic Review of Randomized Controlled Trials
por: Debasu, Zenaw, et al.
Publicado: (2022) -
Rivaroxaban with Aspirin Versus Aspirin for Peripheral Arterial Disease and Intermittent Claudication. Rationale and Design of the COMPASS CLAUDICATION Trial
por: Ramacciotti, Eduardo, et al.
Publicado: (2022) -
Rivaroxaban plus aspirin for the prevention of ischaemic events in patients with cardiovascular disease: a cost-effectiveness study
por: Petersohn, Svenja, et al.
Publicado: (2020)